What is Cardiogen?
Cardiogen is a synthetic four-amino-acid bioregulator identified as Ala-Glu-Asp-Arg (AEDR). It belongs to a family of short peptides developed around proposed tissue-specific signaling.[6][12]
Its cardiac focus comes from experiments on myocardium, the muscle tissue that contracts to pump blood. Other experiments examine the proteins that give cells their shape and support the cell nucleus.[1][6]
Cardiogen’s four-amino-acid AEDR sequence differs from the three-amino-acid sequence AED. It also differs from CardioGen-82, the rubidium-based diagnostic product with a similar name.[6][15]
What Cardiogen is investigated for
Cardiogen evidence is grouped by practical use case and oral and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
Evidence snapshot
Overall confidence
Heart-tissue biology provides a plausible rationale. Clinical benefits for heart function or cardiovascular-event prevention remain unestablished.[1][6][5]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
Human evidence for an independent cardiac treatment benefit remains limited.[5][17]
Animal / preclinical
Preclinical findings concern heart-cell growth and cellular stress; clinical repair benefits remain uncertain.[1][2][3][4]
Mechanism support
Cardiogen may influence heart-cell growth and stress responses, including p53 signaling involved in cell survival.[1]
Forms & administration
Cardiogen has oral capsules and lingual drops, with product-specific preparation and amounts. Intramuscular formulations remain experimental and animal-only.[13][14][18]
Dosing & protocols
These ranges are general reference points, not personal dosing instructions.
Safety profile
Small combined-care reports do not establish common side-effect rates or interactions with heart medicines. Cell and animal findings cannot supply those human safety estimates.[5][17]
Regulatory status
United States
The Cardiogen peptide bioregulator is distinct from CardioGen-82, the rubidium-based diagnostic product. That medicine’s approval does not apply to AEDR capsules or peptide preparations.[15][6]
| Route | FDA drug approval | 503A compounding |
|---|---|---|
| Oral | Not Approved The Cardiogen peptide bioregulator is distinct from CardioGen-82, the rubidium-based diagnostic product. That medicine’s approval does not apply to AEDR capsules or peptide preparations.[15][6] | Not Reviewed Compounding eligibility for this specific preparation has not been confirmed. Drug approval and compounding eligibility are separate questions. |
Oral
FDA drug approval
Not ApprovedThe Cardiogen peptide bioregulator is distinct from CardioGen-82, the rubidium-based diagnostic product. That medicine’s approval does not apply to AEDR capsules or peptide preparations.[15][6]
503A compounding
Not ReviewedCompounding eligibility for this specific preparation has not been confirmed. Drug approval and compounding eligibility are separate questions.
International
Medicinal-product authorization outside the United States remains unconfirmed for the named preparation; status depends on the exact product and country.[15]
Sports & competition
WADA S0 prohibits pharmacological substances without governmental approval for human therapeutic use when no later section addresses them. An unapproved peptide preparation is not athlete-cleared.
How it works
Cardiogen may influence heart-cell growth and stress responses, including p53 signaling involved in cell survival.[1]
AEDR may also affect structural proteins such as actin and tubulin, which help cells maintain their shape and support the nucleus. These are proposed cell-maintenance mechanisms.[6][7]
Research gaps & open questions
What the current literature has not yet settled about Cardiogen:
Controlled trials need to measure symptoms, exercise capacity or cardiac function alongside usual treatment, so that any benefit beyond standard care can be estimated.[5][17]
Human studies need to measure absorption and tissue exposure after an identified AEDR product. Computer predictions about peptide transport cannot establish that capsules deliver an active amount to the heart.[7]
Repeated-course studies need to establish adverse effects and interactions with cardiovascular medicines; the small adjunctive reports cannot quantify those risks.[5][17]
Common questions
Is Cardiogen the three-amino-acid peptide AED?
No. Cardiogen is identified as the four-amino-acid sequence AEDR. The three-amino-acid sequence AED is a different molecule.[6]
History & discovery
Cardiogen emerged from the tissue-specific short-peptide program. Its early cardiac rationale came from organ cultures rather than a patient trial or an approved heart medicine.[3][1]
Investigators examined proliferation and cell-death signaling in heart explants from young and old rats. The findings supported further study of cellular maintenance, without measuring heart function in patients.[1]
A cell study examined the AEDR sequence, while a separate regional report described capsules in twelve patients receiving usual cardiovascular care. The clinical design could not establish an independent treatment effect.[6][5]
18 citations
Cardiogen research focuses on heart-muscle cell maintenance and cellular stress. Clinical evidence remains preliminary, with no established improvement in cardiac pumping function or prevention of cardiovascular events.[1][6][5][7][17][18]
Show citationsHide citations
- [1][The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats]Adv Gerontol, 2009. ex vivo.
- [2]Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent ratsBull Exp Biol Med, 2009 Sep. animal.
- [3][The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats]Adv Gerontol, 2006. in vitro.
- [4][Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging]Adv Gerontol, 2010. in vitro.
- [5]The role of peptide bioregulators in improving treatment effectiveness in elderly patientsVestnik of the Almaty State Institute of Advanced Medical Education, 2012. human clinical.
- [6]Tetrapeptide H-Ala-Glu-Asp-Arg-OH stimulates expression of cytoskeletal and nuclear matrix proteins.Bull Exp Biol Med, 2012 Aug. in vitro.
- [7]Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters.Biomolecules, 2023 Mar. in silico.
- [8]Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide RegulationCells, 2023-01. review.
- [9]Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides.Biochemistry (Mosc), 2013 Feb. in vitro.
- [10]Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers.International journal of molecular sciences, 2022 Jul 13. review.
- [11]Peptide Regulation of Gene Expression: A Systematic Review.Molecules (Basel, Switzerland), 2021 Nov 22. review.
- [12]Site-specific binding of short peptides with DNA modulated eukaryotic endonuclease activity.Bulletin of experimental biology and medicine, 2011 May. in vitro.
- [13]Peptide Bioregulators: Cytomaxes, Cytogens, and LinguaPeptide Product. reference catalog.
- [14]Clinical research with peptide bioregulatorsPeptide Product. reference catalog.
- [15]Drugs@FDA brand/generic name search for CardiogenU.S. Food and Drug Administration, Drugs@FDA via OpenFDA. database query.
- [16]Cardiogen product directionsRLSnet. product directions.
- [17]Cardiogen clinical reportPeptide Bio. human clinical.
- [18]Peptide substance restoring myocardium functionUnited States Patent and Trademark Office, 2010-02-16. patent example.


